Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 176

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial

Röllig, Christoph, Thiede, Christian, Gramatzki, Martin, Aulitzky, Walter, Bodenstein, Heinrich, Bornhäuser, Martin, Platzbecker, Uwe, Stuhlmann, Reingard, Schuler, Ulrich, Soucek, Silke, Kramer, Michael, Mohr, Brigitte, Oelschlaegel, Uta, Stölzel, Friedrich, von Bonin, Malte, Wermke, Martin, Wandt, Hannes, Ehninger, Gerhard, Schaich, Markus, for the Study Alliance Leukemia · 2010 · Blood

Abstract

We present an analysis of prognostic factors derived from a trial in patients with acute myeloid leukemia older than 60 years. The AML96 trial included 909 patients with a median age of 67 years (range, 61-87 years). Treatment included cytarabine-based induction therapy followed by 1 consolidation. The median follow-up time for all patients is 68 months (5.7 years). A total of 454 of all 909 patients reached a complete remission (50%). Five-year overall survival (OS) and disease-free survival were 9.7% and 14%, respectively. Multivariate analyses revealed that karyotype, age, NPM1 mutation status, white blood cell count, lactate dehydrogenase, and CD34 expression were of independent prognostic significance for OS. On the basis of the multivariate Cox model, an additive risk score was developed that allowed the subdivision of the largest group of patients with an intermediate-risk karyotype into 2 groups. We are, therefore, able to distinguish 4 prognostic groups: favorable risk, good intermediate risk, adverse intermediate risk, and high risk. The corresponding 3-year OS rates were 39.5%, 30%, 10.6%, and 3.3%, respectively. The risk model allows further stratification of patients with intermediate-risk karyotype into 2 prognostic groups with implications for the therapeutic strategy. This study was registered at www.clinicaltrials.gov as #NCT00180115.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2010-01-267302

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 176

Metadata

Authors
Röllig, C., Thiede, C., Gramatzki, M., Aulitzky, W., Bodenstein, H., Bornhäuser, M., Platzbecker, U., Stuhlmann, R., Schuler, U., Soucek, S., Kramer, M., Mohr, B., Oelschlaegel, U., Stölzel, F., von Bonin, M., Wermke, M., Wandt, H., Ehninger, G., Schaich, M., & for the Study Alliance Leukemia
Venue
Blood
Published
2010-08-12
Volume
116
Issue
6
Pages
971-978
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2065464763
Cited by
176
References
2
FWCI
8.98
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. https://app.cochat.ai/papers/10.1182/blood-2010-01-267302
The paper
Röllig, C., Thiede, C., Gramatzki, M., Aulitzky, W., Bodenstein, H., Bornhäuser, M., Platzbecker, U., Stuhlmann, R., Schuler, U., Soucek, S., Kramer, M., Mohr, B., Oelschlaegel, U., Stölzel, F., von Bonin, M., Wermke, M., Wandt, H., Ehninger, G., Schaich, M., & for the Study Alliance Leukemia. (2010). A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. Blood. https://doi.org/10.1182/blood-2010-01-267302

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.